SCR-LIP-000671 · Claim · machine-readable JSON →

The proposed rationale for gestrinone in lipedema rests on hypothesised aromatase inhibition and estrogen-receptor blockade, supported only by theoretical and in vitro data.

General proposition consolidated from 1 earlier single-paper claims; each study's own result is shown as its finding.

Claim at a glance
Type
clinical association
Knowledge state
Emerging
Evidence certainty
very low (GRADE)
Evidence
1 source(s)
Dates
2026-11-20 → 2026-11-20

Structured evidence, machine-compiled — not a verdict.

Evidence over time

2024Effects, Doses, and Applicability of Gestrinone in Estrogen-Dependent Conditions and Post-Menopausal Women — Renke et al. (2024) · consistent

Evidence (1)

Context (PECO)

Populationwomen with lipedema (hypothetical/proposed)
Conditionlipedema
Exposuregestrinone (aromatase inhibitor, ER blocker)
Outcomemechanistic rationale; in vitro cell viability only
Scopeauto-ingested from Layer 1 surveillance

Answers these questions

Gaps & caveats

Change log